Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 847 (1 August 2008) | doi:10.1038/nbt0808-847a
Pharma to boycott UK?
Abstract
From being one of the least regulated markets in Europe, the new agreement will move the UK to one of the most heavily regulated, Andrew Monro, a partner at consultancy KPMG in London, points out. He says big biotech and pharma companies particularly resent the fact that the government refuses to allow them to market their entire product portfolio in the UK—and now it wants explicit price control for the limited portfolio it does allow.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
